The long-term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States

Hepatology

Volumn 29, Issue 4, 1999, Pages 1311-1316

  Hu, Ke Qin ^a   Tong, Myron J ^a  

^a HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

EID: 0032955838     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290424     Document Type: Article

References (29)

1. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
2. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G, et al. Long-term fellow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-281.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
4. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. HEPATOLOGY 1997;26(Suppl 1):34S-38S.
5. Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997;26(Suppl 1):21S-28S.
6. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, Lee CA, et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
7. Roudot-Thoraval F, Bastie A, Pawlotsky J-M, Dhumeaux D, et al. Epidemiological factors affecting the severity of hepatitis C virus-related disease: a French survey of 6,664 patients. HEPATOLOGY 1997;26:485-490.
8. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois, C, Chretien Y, Poupon RE, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. HEPATOLOGY 1997;26:776-779.
9. Fattovich G, Giustina G, Gegos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
10. Serfaty L, Aumitre H, Chazouilieres, O, Bonnand A-M, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. HEPATOLOGY 1998;27:1435-1440.
11. Lindsay K. Therapy of hepatitis C: overview. HEPATOLOGY 1997;26(Suppl1):71S-77S.
12. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. HEPATOLOGY 1997;26:780-785.
13. Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. HEPATOLOGY 1997;26(Suppl 1):83S-88S.
14. Nishigushi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomised trial of effects of interferon-alfa on incidence of hepatocelular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
15. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. HEPATOLOGY 1998;27:1394-1402.
16. Fattovich G, Giustina G, Gegos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in Europe patients with cirrhosis type C. J Hepatol 1997;27:201-205.
17. Mazzella G, Accogli E, Scottili S Festi D, Orsini M, Salzetta A, Novelli V, et al. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
18. Bianchi L, De Groote J, Desmet VJ, Gedik P, Korb G, Popper H, Poulsen H, et al. Acute and chronic hepatitis revisited. Lancet 1977;2:914-919.
19. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterology 1997;92:1302-1304.
20. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997;26:747-754.
21. Simmonds P, Alberti P, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT. A proposed system for the nomenclature of hepatitis C viral ' genotypes. HEPATOLOGY 1994;19:1321-1324.
22. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
24. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. HEPATOLOGY 1998;28:562-567.
25. Nishioka K, Watanabe J, Furuta S, Tanaka E, Lino S, Suzuki H, Tsuji T, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;61:429-433.
26. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, et. al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-938.
27. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. HEPATOLOGY 1991;14:969-974.
28. Koretz, RL, Abbet H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993;119:110-115.
29. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. HEPATOLOGY 1998;28:1687-1695.